Designing and Analyzing Factorial Trials in Veterinary Research

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Factorial designs efficiently evaluate multiple interventions simultaneously by crossing all levels of each factor, allowing for the assessment of independent effects (main effects) and combined effects that differ from the sum of individual effects (interactions). A 2x2 factorial design, for instance, requires no more subjects than a single-factor trial at equivalent power if effects are additive, yet yields information on both treatments and their joint behavior.
• The interpretation of main effects in factorial trials is only straightforward when interactions are absent or explicitly modeled; a significant interaction indicates that the effect of one factor is dependent on the level of another, rendering averaged main effects potentially misleading. For example, a dietary supplement might improve weight gain in healthy animals but impair it in diseased animals, a qualitative interaction that a simple main effect would obscure.
• Sample size calculations for factorial trials should prioritize power for detecting interactions, as these are often the most critical estimands and require substantially larger sample sizes than main effects of equivalent magnitude. A trial powered solely for main effects may be severely underpowered for interaction detection, leading to misinterpretation if a significant interaction is present but not detected.
• Analysis of factorial trials necessitates fitting a full model including interaction terms first; if the interaction is not statistically significant (conventionally P > 0.10 for screening), the model can be refitted without it to interpret main effects. If the interaction is significant, analysis must focus on simple effects (the effect of one factor at each level of the other) with appropriate adjustments for multiple comparisons.
• Reporting of factorial trials must adhere to standards like ARRIVE 2.0 for animal research or CONSORT/REFLECT for clinical trials, explicitly stating whether interaction terms were tested, how the model was reduced, and how main effects are reported in the presence of interaction. This includes transparent reporting of allocation concealment, blinding, and the statistical analysis plan.
• Common analytical errors include treating factors as independent single-factor experiments, which inflates Type I error and masks interactions, or interpreting main effects in the presence of a significant interaction. Corrective actions involve fitting a single model with interaction terms and reporting simple effects when interactions are present.

Factorial trials allow veterinary researchers to evaluate two or more interventions in a single experiment, with every combination of treatment levels assigned to a distinct group. This design answers questions that single-factor trials cannot: whether treatments act independently or whether their combined effect differs from the sum of their separate effects. The present article explains the logic of factorial design, the meaning of main effects and interactions, sample size planning, and the analytical decisions that determine whether a factorial trial yields interpretable results. It is written for veterinary researchers planning clinical trials, experimental infection studies, or production-system evaluations across species.

The central distinction a factorial trial makes is between a main effect and an interaction. A main effect is the average effect of one factor across all levels of the other factor. An interaction exists when the effect of one factor depends on the level of the other. A 2 x 2 factorial trial, the most common form, assigns subjects to one of four combinations: factor A absent or present, crossed with factor B absent or present. This design requires no more subjects than a trial testing either factor alone at the same power, provided the factors act additively, yet it yields information on both treatments and their joint behavior. The efficiency is genuine, but it comes with a condition: the interpretation of main effects is straightforward only when interaction is absent or explicitly modeled.

The logic of factorial design extends beyond clinical therapeutics. In a study of weaned piglets, dietary oil source and immunological challenge were crossed in a 2 x 2 arrangement to test whether fish oil modified the intestinal response to lipopolysaccharide fish oil and intestinal integrity in weaned pigs after LPS challenge. The factorial structure allowed the authors to separate the nutritional effect, the challenge effect, and the possibility that fish oil specifically blunted the challenge response. A single-factor design could not have distinguished a general protective effect from one that operates only under inflammatory stress. Similar reasoning applies in reproductive biology, where a four-factor factorial trial in canine semen processing evaluated extender additives, dilution steps, freezing method, and thawing rate in one experiment, with interaction terms identifying combinations that performed better or worse than the additive prediction Equex, dilution, and freezing and thawing rates on dog spermatozoa survival.

At a Glance

The Structure of Factorial Experiments

A factorial experiment is defined by crossing every level of each factor with every level of every other factor. In a 2 x 2 design, four groups result. In a 2 x 2 x 2 design, eight groups result. The number of groups grows multiplicatively, which is both the strength and the constraint of the approach. Full factorial designs estimate all interactions, but the number of subjects required to detect higher-order interactions can become prohibitive. Fractional factorial designs, which deliberately confound some interactions with main effects, exist but are rarely appropriate for veterinary clinical trials where the interaction itself is often the question of interest.

The assignment of subjects to combinations must be random. Blocking by relevant covariates, such as herd, litter, or body weight, preserves the factorial structure while reducing error variance. The key requirement is that every combination appears in every block, or that the design remains balanced enough for the analysis to separate factor effects from block effects.

Main Effects and Interaction

A main effect is computed by averaging over the levels of the other factor. In a 2 x 2 trial, the main effect of factor A is the difference between the mean of all subjects receiving A and the mean of all subjects not receiving A, pooling across both levels of B. This averaging is meaningful only when the effect of A is similar at both levels of B. When it is not, the main effect describes a weighted average that may not apply to any actual group.

Interaction is the statistical expression of non-additivity. On the additive scale, the combined effect of A and B equals the sum of their separate effects. An interaction on the additive scale means the combined effect is larger or smaller than that sum. The scale matters. Two factors may show no interaction on a logarithmic scale while showing substantial interaction on the raw scale, and vice versa. For outcomes such as bacterial counts, lesion scores, or survival times, the choice of scale is a scientific decision, not a statistical afterthought.

The human neonatal hypothermia trial illustrates the practical stakes of interaction. A 2 x 2 factorial randomized neonates to two durations and two depths of cooling, and the trial was stopped early when the independent data and safety monitoring committee found an emerging safety profile and futility at the eighth interim review depth and duration of cooling in neonatal hypoxic ischemic encephalopathy. The factorial structure allowed the monitoring committee to assess whether the two factors, duration and depth, posed independent risks or whether their combination was particularly hazardous. The decision to stop was not based on a single main effect but on the joint behavior of both factors across all four groups.

The Efficiency Argument and Its Limits

The claim that a factorial trial tests two interventions for the price of one rests on the assumption of additivity. When interaction is absent, the variance of each main effect estimate is approximately the same as it would be in a single-factor trial with the same total sample size. This efficiency is real and has made factorial designs attractive in fields where subject recruitment is difficult. The WAVE trial used a 2 x 2 factorial to test hormone replacement therapy and antioxidant vitamins in postmenopausal women with coronary disease, randomizing 423 participants to four combinations hormone replacement therapy and antioxidant vitamins on coronary atherosclerosis. The design permitted simultaneous evaluation of two widely used interventions in a population that was difficult to enroll.

The efficiency disappears when interaction is large. If the effect of A is positive in the absence of B and negative in the presence of B, the main effect of A may be near zero, and the trial may conclude that A has no effect when in fact it has a strong, context-dependent effect. Sample size calculations for factorial trials should therefore be based on the smallest effect the study must detect, which is often the interaction, not the main effect. A trial powered only for main effects may be severely underpowered for the interaction that determines whether those main effects are interpretable.

Reporting Standards

Factorial trials in veterinary medicine should be reported according to the same standards as other controlled experiments. The ARRIVE guidelines 2.0 specify the minimum information required for transparent and reproducible animal research, including sample size justification, randomization, blinding, and statistical methods ARRIVE guidelines 2.0 for reporting animal research. For clinical trials in livestock or companion animals, the EQUATOR Network library provides reporting checklists including CONSORT and REFLECT, the latter adapted for randomized controlled trials in livestock EQUATOR Network reporting guidelines library. These standards require authors to state whether interaction terms were tested, how the model was reduced, and whether main effects are reported in the presence of interaction.

Designing the 2 × 2 Factorial Trial: A Worked Example

Consider a common veterinary research question: does adding an analgesic to a standard anti-inflammatory protocol improve recovery in dogs undergoing ovariohysterectomy, and does the timing of administration matter? A 2 × 2 factorial design can answer both questions in a single trial. Factor A is drug regimen, with levels standard nonsteroidal anti-inflammatory drug (NSAID) alone or NSAID plus a second analgesic class. Factor B is timing, with levels preoperative or postoperative administration. The four cells are NSAID alone preoperatively, NSAID alone postoperatively, NSAID plus adjunct preoperatively, and NSAID plus adjunct postoperatively.

The primary outcome might be a validated pain score measured at 2, 6, 12, and 24 hours after extubation, with the area under the curve as the summary measure. Secondary outcomes could include rescue analgesia requirements, time to first voluntary food intake, and adverse event frequency.

Sample size calculation proceeds from the main effects. Suppose the investigators expect the adjunct analgesic to reduce the mean pain score area under the curve by 20% relative to NSAID alone, with a coefficient of variation of 40%. They also expect preoperative timing to reduce the score by 15%. The larger of the two expected effects, the 20% reduction, drives the sample size if both main effects are of equal importance. Using standard formulae for a two-arm comparison with alpha 0.05 and power 0.80, and assuming a two-sided test, the required number per group is approximately 63. In a factorial trial, each main effect is estimated using all animals, so the total sample size is 126, not 252. This is the efficiency advantage described in the earlier section on factorial structure.

The calculation changes if an interaction is anticipated. If the investigators suspect that the adjunct works only when given preoperatively, the interaction term becomes a primary focus. Detecting an interaction of clinically meaningful size requires roughly four times the sample size needed to detect a main effect of the same magnitude. A trial powered only for main effects will be severely underpowered for interaction detection, and the analysis will mislead if an interaction is present but not modelled.

Allocation and Blinding

Randomisation should stratify by factors that influence the outcome, such as baseline body weight, age, and surgeon. Block randomisation within strata keeps group sizes balanced. The allocation sequence should be generated by an independent statistician and concealed until the moment of intervention. Blinding is feasible in this design: the anesthetist can prepare identical syringes labelled only with a code, and the assessor scoring pain can remain unaware of group assignment. Where blinding is impossible, such as in some surgical trials comparing techniques, the outcome assessor should still be masked to treatment allocation. The ARRIVE guidelines for reporting animal research specify blinding and allocation concealment as minimum reporting items, and reviewers increasingly expect explicit description of these procedures.

Analysis Strategy

The analysis begins with a check of baseline comparability across the four cells. Descriptive statistics for age, weight, and baseline pain scores should be tabulated by cell. Formal hypothesis testing of baseline variables is not recommended, because any imbalance arises by chance and the test does not correct it.

The primary analysis uses a two-way analysis of variance with drug regimen, timing, and their interaction as fixed effects. The interaction term is tested first. If the interaction is not significant at a prespecified level, conventionally P greater than 0.10 for a screening test, the model is refitted without the interaction and the main effects are interpreted. If the interaction is significant, main effects cannot be interpreted in isolation. The analysis must instead present simple effects, the effect of drug regimen within each timing level, with appropriate adjustment for multiple comparisons.

The choice of significance threshold for the interaction screening test deserves explicit justification. A threshold of 0.10 is common because it protects against missing a real interaction that would invalidate main effect interpretation. Some statisticians prefer to retain the interaction term regardless of its P value when the trial was not powered to detect it, arguing that the main effects are then conditional and less misleading. The decision should be made at the design stage and stated in the analysis plan.

Interpretation Guide

Interpretation follows a decision tree. If the interaction is absent, report both main effects with confidence intervals. The confidence interval for each main effect is narrower than it would be in a single-factor trial because all animals contribute to both estimates. If the interaction is present, the scientific question shifts from which factor works to which combination works. The four cell means are compared, and the analysis emphasizes the pattern of non-additivity.

A worked interpretation for the hypothetical trial: the interaction test yields P = 0.35, so the interaction is dropped. The main effect of drug regimen shows a mean reduction of 18% in pain score area under the curve with the adjunct (95% confidence interval 8% to 28%, P = 0.001). The main effect of timing shows a mean reduction of 12% with preoperative administration (95% confidence interval 2% to 22%, P = 0.02). Both main effects are clinically meaningful and statistically significant. The conclusion is that the adjunct reduces pain and preoperative timing reduces pain, and these effects are additive.

If instead the interaction test yields P = 0.02, the interpretation changes. The cell means show that the adjunct reduces pain when given preoperatively but has no effect when given postoperatively. The main effect of drug regimen, averaged across timing levels, is misleading because it obscures this conditional effect. The report must present the simple effects and state that the benefit of the adjunct depends on timing.

Species and Context Modifications

The worked example uses dogs, but the design transfers across species with adjustments. In production animals, the unit of allocation may be the pen or herd instead of the individual, and the analysis must account for clustering. A factorial design with pen-level allocation requires a mixed model with pen as a random effect, and the sample size calculation must inflate for the intracluster correlation. In horses, the cost per animal is high and the number available is limited, so a factorial design is attractive for its efficiency, but the risk of an undetected interaction is correspondingly more serious. In cats, the higher frequency of adverse drug reactions may argue for a larger safety margin in sample size.

The choice of outcome measure also varies. Pain scoring in dogs and cats uses validated composite scales, but in cattle and sheep behavioral and production outcomes such as weight gain or milk yield may be more practical. The MSD Veterinary Manual provides species-specific guidance on pain assessment and drug selection that should inform outcome choice. In food animals, withdrawal periods constrain the choice of interventions and may affect feasibility of the trial design.

Monitoring and Stopping Rules

Factorial trials require prespecified monitoring rules. The trial should define stopping criteria for harm, such as an excess of adverse events in any cell, and for futility. The neonatal hypothermia trial that used a 2 × 2 factorial design was paused repeatedly by its data and safety monitoring committee to evaluate cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and death, and was ultimately closed for emerging safety profile and futility after the eighth review. Veterinary trials should adopt a similar approach, with an independent monitor reviewing accumulating data at prespecified intervals. The monitoring plan should state the adverse event rates that trigger review and the statistical criteria for early stopping.

Documentation and Reporting

The analysis plan should be registered before enrollment begins. Any deviation from the plan, such as changing the interaction screening threshold or the primary outcome, must be reported with justification. The final report should include a table of cell means with standard deviations, the interaction test result, and the main effect estimates with confidence intervals. The EQUATOR Network reporting guidelines catalogue the relevant checklists, and the ARRIVE guidelines specify the minimum information for transparent reporting of animal research. A completed CONSORT-style flow diagram showing the number of animals screened, randomised, and analyzed in each cell should accompany the report.

The report should also state the precision of the estimates, also whether the P value crossed a threshold. A main effect that is statistically significant but clinically trivial should be described as such. Conversely, a nonsignificant interaction with a wide confidence interval does not prove the absence of interaction, the report should acknowledge the limited power to detect interactions and describe the observed interaction effect size with its confidence interval.

Recognized Complications and Early Detection

Factorial trials in veterinary research fail in characteriztic ways. The most common complication is the emergence of a qualitative interaction, where the effect of one factor reverses depending on the level of the other. A dietary supplement that improves weight gain in healthy animals but impairs it in diseased animals is a qualitative interaction. These are detected early by plotting treatment means at each interim analysis and inspecting whether the lines connecting factor levels cross. Crossing lines warrant caution even when the interaction term is not yet statistically significant, because power for interaction tests is low.

A second complication is differential dropout across the four cells of a 2 × 2 design. If animals receiving the combined treatment are more likely to be withdrawn because of adverse events, the remaining animals in that cell are a selected subset. Monitor cell-specific dropout rates at each scheduled review. A difference of more than 10 percentage points between cells should trigger a formal assessment of whether missingness is related to the outcome.

A third failure mode is the silent loss of factorial structure through protocol violations. Crossovers between treatment arms, incorrect dosing, or contamination of the control diet with the active ingredient collapse the design toward a series of uncontrolled comparisons. Track protocol adherence by cell, not by factor, because violations often cluster within one combination.

Common Errors and Corrective Action

Less experienced investigators frequently analyze factorial data as if each factor were a separate single-factor experiment. They conduct two independent t tests, one per factor, and report the results separately. This approach inflates the type I error rate and, more seriously, makes a true interaction undetectable. The corrective action is to fit a single model containing both main effects and the interaction term, and to report the interaction test before interpreting either main effect.

A second recurring error is the interpretation of main effects in the presence of a significant interaction. When the interaction is real, the main effect of each factor is an average across the levels of the other factor and may not describe any actual treatment contrast. The correct approach is to estimate simple effects, the effect of one factor at each level of the other, and to present those estimates with confidence intervals.

A third error is the use of a Bonferroni correction across all pairwise comparisons among the four cells. This is overly conservative because the factorial structure provides a prespecified set of contrasts that are orthogonal. The analysis should test the interaction, then the two main effects, and only then, if warranted, specific cell contrasts. The reporting standards in the ARRIVE guidelines for animal research require that the statistical model be described in sufficient detail that a reader can verify the analysis plan was followed.

Limitations of the Evidence and Divergent Expert Opinion

The factorial design is efficient, but its efficiency rests on assumptions that are not always met. The most important assumption is that the two factors act additively on the chosen scale. When the outcome is binary, additivity on the odds ratio scale does not imply additivity on the risk difference scale, and the choice of scale can change whether an interaction appears. Expert opinion differs on whether interactions should be tested on the natural or transformed scale, and the decision should be made at the design stage, not after inspecting the data.

A second area of disagreement concerns the handling of interactions that are not statistically significant but are clinically plausible. Some authorities recommend retaining the interaction term in the model regardless of its p value, because removing it can bias the main effect estimates. Others recommend a hierarchical approach in which the interaction is removed if its p value exceeds a threshold such as 0.10. The choice affects the width of confidence intervals and the interpretation of the main effects.

The evidence base for factorial trials in veterinary medicine is thinner than in human medicine. The Women's Angiographic Vitamin and Estrogen trial demonstrates the value of the design in human cardiology, and the neonatal hypothermia trial shows how a 2 × 2 factorial can be stopped early for safety, but comparable veterinary examples are fewer and often smaller. The weaned piglet study on fish oil and LPS challenge is a well-executed 2 × 2 factorial, yet its sample size of 24 animals limits the precision of the interaction estimate. Extrapolating from these studies to other species and production systems requires caution.

Escalation and Consultation

Referral to a consulting biostatistician is warranted when the interaction term is significant but the direction of effects is clinically implausible, when dropout patterns threaten the validity of the analysis, or when the trial must be stopped early and the final analysis requires methods that account for the interim review. Laboratory involvement may be needed to verify that the intervention was delivered as intended, for example by measuring the active compound in feed or plasma. Regulatory reporting is required when an unexpected adverse event pattern emerges, particularly in food-producing species, and the World Organization for Animal Health terrestrial animal health standards should be consulted for notifiable conditions. The AVMA practice resources provide guidance on professional obligations when a trial reveals a safety concern that affects clinical patients.

Frequently Asked Questions

How do I justify a factorial design when my funding agency expects a conventional single-intervention trial?

Frame the factorial design as two trials conducted within one experiment. The efficiency argument is strongest when both interventions are inexpensive, low-risk, and unlikely to interact. Prepare a sample size table showing the power available for each main effect under the factorial allocation, and compare that against the cost of two separate trials. Emphasize that the factorial design also provides the interaction test, which a pair of single-intervention trials cannot deliver. If the agency remains sceptical, offer a fallback analysis plan that reports each main effect stratified by the other factor, which preserves interpretability even if the interaction term is non-significant.

What should I do when one of my two factors performs poorly in practice, such as poor treatment compliance or failed blinding?

Pre-specify how you will handle incomplete delivery of either intervention. The primary analysis should follow the intention-to-treat principle, assigning animals to the groups they were randomised to receive. A per-protocol secondary analysis can estimate efficacy under full delivery, but interpret it cautiously because compliance is rarely random. If one factor fails entirely, the trial degrades to a single-factor comparison for the other factor, and the interaction estimate becomes uninformative. Report the failure transparently and state its impact on the precision of each estimate. The ARRIVE reporting guidelines require explicit description of deviations from the planned interventions.

How does the factorial analysis change when I include a continuous covariate such as body weight or age?

Include the covariate in the analysis model as a fixed effect, provided it was measured before randomisation and is not affected by either intervention. The covariate reduces residual variance and increases power for both main effects and the interaction. Check that the covariate does not interact with either treatment factor, if it does, the treatment effect estimates become conditional on the covariate value. For veterinary growth studies, baseline weight often correlates strongly with outcome, so adjusting for it can substantially improve precision. Report both unadjusted and adjusted estimates. The EQUATOR Network reporting guidelines list the items needed to describe covariate adjustment transparently.

Can I use a factorial design when my outcome is survival time or time to recovery?

Yes, but the analysis shifts to a time-to-event framework. The Cox proportional hazards model can include both factors and their product term as covariates. The interaction is then a test of whether the hazard ratio for one factor differs across levels of the other. Sample size calculations require assumptions about event rates and follow-up duration, also effect sizes. Competing risks, such as euthanasia for unrelated causes, need explicit handling. The factorial structure does not complicate the survival analysis itself, but censoring patterns must be balanced across the four cells. Consult a statistician before finalising the protocol if you anticipate heavy censoring.

How do I explain the interaction effect to a referring veterinarian or a practice owner who expects a simple answer?

Use a concrete clinical example. State that the interaction answers the question of whether the benefit of treatment A depends on whether treatment B was also given. If the interaction is significant, present the four group means or survival curves instead of the two main effects alone. If the interaction is not significant, you can report the main effects as the average effect of each treatment across the other factor. Avoid language that implies one treatment cancels another unless the data show that pattern. A figure with the four groups plotted separately is usually clearer than a table of coefficients.

What are the minimum record-keeping requirements for a factorial trial to be auditable and reproducible?

Maintain a versioned protocol, a randomisation log that links each animal identification number to its allocated group, and a complete dataset with all measured variables and dates. Record the batch and lot numbers of both interventions, storage conditions, and administration times. Document any animal removed from the study with the reason and the date. Keep the statistical analysis code or spreadsheet formulas in a form that a second analyst can run. The ARRIVE guidelines specify the minimum information for transparent reporting, and institutional or professional practice resources may impose additional requirements depending on your jurisdiction and funding source.

Related Clinical & Scientific Guides

• Conducting Systematic Reviews of Veterinary Diagnostic Test Accuracy
• Bias in Veterinary Research: Types, Sources, and Mitigation
• Cluster Randomized Trials in Veterinary Research: Design and Analysis

References and Further Reading

• Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial.. 2014.
• Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.. 2002.
• Fish oil enhances intestinal integrity and inhibits TLR4 and NOD2 signaling pathways in weaned pigs after LPS challenge.. 2012.
• Interaction of pollinators and herbivores on plant fitness suggests a pathway for correlated evolution of mutualism- and antagonism-related traits.. 2002.
• Effects of Equex, one- or two-step dilution, and two freezing and thawing rates on post-thaw survival of dog spermatozoa.. 2000.
• Sub-second Dopamine and Serotonin Signaling in Human Striatum during Perceptual Decision-Making.. 2020.
• ARRIVE Guidelines 2.0 for Reporting Animal Research. PLOS Biology, 2020.
• EQUATOR Network Reporting Guidelines. EQUATOR Network.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Designing Crossover Trials for Veterinary Therapeutics
• Designing Questionnaire Studies for Veterinary Research
• Cluster Randomized Trials in Veterinary Research: Design and Analysis
• Designing Adaptive Clinical Trials for Veterinary Medicine
• Cohort Studies in Veterinary Research: Design and Interpretation

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.